Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure
Author(s) -
Jay N. Cohn
Publication year - 2003
Publication title -
journal of the renin-angiotensin-aldosterone system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 46
eISSN - 1752-8976
pISSN - 1470-3203
DOI - 10.3317/jraas.2003.021
Subject(s) - heart failure , angiotensin receptor blockers , renin–angiotensin system , angiotensin converting enzyme , pharmacology , medicine , angiotensin receptor , enzyme inhibitor , angiotensin ii receptor type 1 , angiotensin ii , receptor , cardiology , endocrinology , enzyme , chemistry , blood pressure , biochemistry
The renin-angiotensin-aldosterone system contributes to the progression of heart failure and its inhibition slows ventricular remodelling and favourably affects morbidity and mortality. -blockers exert a remarkably favourable effect on progression that may be mediated at least in part by renin inhibition. Although earlier trials suggested a possible adverse interaction when an angiotensin receptor blocker was added to an angiotensin-converting enzyme inhibitor and a -blocker, a recent study and newly analysed mechanistic data indicate that the triple combination provides modest additional inhibition of angiotensin that can further slow progression of disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom